Fitzsimons Innovation Community
Fitzsimon_menu

Find out what's happening on campus and across the industry.

Read Fitzsimons Innovation Community news, industry highlights, editorials, and innovation updates happening weekly on our campus.

Blog
Adams County Economic Development: On the Frontlines of Growth in Colorado
July 25, 2024
Blog
Fitzsimons Innovation Community Master Plan: Holistic. People-Focused. Community-Forward.
June 27, 2024
Blog
Bringing Life Sciences Innovators Home to Colorado
May 20, 2024
Adams County Economic Development: On the Frontlines of Growth in Colorado
Blog | Jul 25, 2024

Adams County Economic Development: On the Frontlines of Growth in Colorado

If you ask the Economic Development team for Adams County Government what drives them, they’ll tell you it’s their goal of being the most inclusive and innovative county in America. Fitzsimons Innovation Community is proud to call Adams County home, and our recent conversation with the leaders of the Adams County Government office only reinforced that pride. We spoke this month with Lucas Workman, Economic Development Manager, and Caroline Joy, Community and Economic Development Marketing Lead about the goals and visions the Adams County Government has for one of the fastest growing and most popular counties in Colorado. What we found out is that Adams County is the perfect blend of urban and rural amenities, affordability, and quality of life, and that the economic development of the county is in very capable hands.

Pioneers in Health Care
News | Jul 22, 2024

Pioneers in Health Care

Fitzsimons Innovation Community is home to more than 80 health and life sciences companies whose live-saving scientific research is blazing the trail for medical advancements and curing diseases, improving patient care, and saving lives. Livability (Adams County) features vignettes of three entrepreneurs conducting groundbreaking research on site.

Fitzsimons Innovation Community Features Among the “Titans of Transformation”
News | Jul 22, 2024

Fitzsimons Innovation Community Features Among the “Titans of Transformation”

Fitzsimons Innovation Community is recognized for having made a profound impact on the region’s economy in the annual issue of Livability (Adams County). Last fall, AC-REP honored Fitzsimons with their Gamechanger award for driving economic vitality.

Atara Biotherapeutics
News | Jul 17, 2024

Atara Biotherapeutics

Today Atara announced that the FDA has accepted its Biologics License Application (BLA) and granted Priority Review with a January 15, 2025 hashtag#PDUFA date for tabelecleucel (tab-cel®) as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus (hashtag#EBV) positive post-transplant lymphoproliferative disease (hashtag#PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate. If approved, tab-cel would be the first approved therapy in the U.S. for EBV+ PTLD. Read the press release for more: https://bit.ly/46bainx

DARTNet enhances and enlarges clinical decision support for clinicians
News | Jul 03, 2024

DARTNet enhances and enlarges clinical decision support for clinicians

DARTNet leaders Wilson Pace and John Westfall co-author "An Exploratory Study of Physician Decision-Making When Treating Uncontrolled COPD" in International Journal of Chronic Obstructive Pulmonary Disease.

Companies selected to present at CBSA’s 2024 Rocky Mountain Life Sciences Investor & Partnering Conference
News | Jul 02, 2024

Companies selected to present at CBSA’s 2024 Rocky Mountain Life Sciences Investor & Partnering Conference

Congratulations to the startup, emerging, and growth companies selected to present at CBSA’s 2024 Rocky Mountain Life Sciences Investor & Partnering Conference, chosen by a panel of experts. Shout out to Fitzsimons Innovation Community Members, EnteroTrack, GelSana, RheumaGen, and Vona Oncology. among those selected.

Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute
News | Jul 01, 2024

Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute

Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement. Gates Institute will leverage Charles River’s premier cell and gene therapy CDMO expertise to develop Good Manufacturing Practice (GMP)-grade lentiviral vectors (LVVs) for use in novel chimeric antigen receptor (CAR) T-cell therapies for hematological cancers.

Colorado Tech Blog Features GelSana’s Innovative Materials
News | Jul 01, 2024

Colorado Tech Blog Features GelSana’s Innovative Materials

Colorado Tech Spotlight features a profile of GelSana and how this Fitzsimons Innovation Community company is disrupting the field of wound care. Discover how it works, the story behind it, and how the Colorado life sciences and medical technology community comes together to collaborate and grow our state's prominence in the field.

Fitzsimons Innovation Community Master Plan: Holistic. People-Focused. Community-Forward.
Blog | Jun 27, 2024

Fitzsimons Innovation Community Master Plan: Holistic. People-Focused. Community-Forward.

In creating the plan for a 184-acre innovation campus, Fitzsimons Innovation Community leadership always knew there would be room for change and adaptability down the road. Over a 20-year period, technology and policies change, new information comes to light, and we gain a better understanding of what our Community members need to succeed. Focused on the ‘whole person,’ the update of our Master Plan seeks to build out the Community core in a way that supports research, learning, and living. Today, we have facilities, infrastructure, and wrap-around services for 25,000 researchers, faculty, and staff, along with 4,500 future health professionals. As the campus continues to grow, we will also evolve into a fully integrated, live-work-play-learn environment emphasizing personal health and wellbeing for every individual on campus, with access to the resources needed for groundbreaking life sciences research and transformative healthcare.

Paving the Way Toward Transplantation: NIH Awards Support Ophthalmology Retinal Research
News | Jun 26, 2024

Paving the Way Toward Transplantation: NIH Awards Support Ophthalmology Retinal Research

CellSight researchers have been granted funding from the National Institutes of Health to better understand retinal cells differentiation and mechanisms for successful stem cell-derived 3D retinal transplants in patients with age-related macular degeneration (AMD).

Expanding the Vision for Fitzsimons Innovation Community
News | Jun 10, 2024

Expanding the Vision for Fitzsimons Innovation Community

Fitzsimons Innovation Community is expanding life sciences innovation in the region with an updated mater plan for the 184-acre innovation campus to the north of the world-renowned University of Colorado Anschutz Medical Center. The innovation community is currently home to more than 80 visionary companies taking their research to the next level to cure disease, save lives and improve care. Centrally located within 20 minutes of Denver International Airport, downtown Denver and the Denver Tech Center, Fitzsimons Innovation Community is custom-built for discovery with state-of-the-art facilities and flex spaces, opportunities for strategic partnerships and collaboration, a broad range of community amenities and the best of the Colorado lifestyle.

Lohocla Research Announces FDA Clearance of Investigational New Drug Application for Kindolor, a Novel Medicinal Molecule for Treating Chronic Pain
News | May 30, 2024

Lohocla Research Announces FDA Clearance of Investigational New Drug Application for Kindolor, a Novel Medicinal Molecule for Treating Chronic Pain

Focusing on non-addictive treatments for chronic pain and addiction, Lohocla Research Corporation gets the go-ahead for first-in-human trials of their first-in-class therapeutic for chronic pain syndromes.

Load More
© 2024

 Fitzsimons Innovation Community